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Plasma MMP-9 – a Marker of Carotid Plaque Instability†
I. M. Loftus∗, A. R. Naylor, P. R. F. Bell and M. M. Thompson
Department of Surgery, Leicester University, Leicester, U.K.
Objectives: to investigate whether peripheral blood levels of matrix metalloproteinases (MMPs) or their inhibitors are
altered in patients with particulate cerebral embolisation.
Design: a prospective study.
Materials and methods: using sandwich enzyme immunoassay, plasma levels of MMPs-1, -2, -3 and -9, plus TIMPs-
1 and -2 were quantified in 70 consecutive patients undergoing carotid endarterectomy. Patients were monitored with
transcranial Doppler (TCD) preoperatively and during the dissection phase of the operation to detect those with spontaneous
particulate embolisation (n=21).
Results: the plasma level of MMP-9 was significantly higher in those patients with evidence of spontaneous embolisation
compared to those without. There were no differences in other MMP levels, or plasma concentrations of TIMPs.
Conclusions: plasma MMP-9 levels are elevated in patients with particulate cerebral embolisation, and this may represent
a novel marker of atherosclerotic plaque instability.
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Introduction the main physiological regulators of the extracellular
matrix. Secreted in a latent pro-enzyme form by a
range of cell types, including inflammatory cells,The atherosclerotic plaque is a dynamic structure,
fibroblasts and smooth muscle cells, they require ac-undergoing continuous remodelling of the extra-
tivation by limited proteolysis. There is evidence link-cellular matrix upon which its structural integrity
ing MMPs to disease states in which tissue degradationdepends. Acute changes within the plaque are a pre-
plays a key role, including aneurysmal disease,8,9 can-lude to the onset of clinical ischaemic events.1 If the
cer,10,11 and arthritis.12 Their role in pathological statesplaque undergoes acute disruption such as rupture or
has led to the development of specific inhibitors, someulceration, exposure of highly thrombogenic material
of which are currently involved in clinical trials.13in the plaque core leads to thrombus formation. Sec-
Initial plaque disruption has been shown to occurondary thrombo-embolism may then cause stroke.
predominantly in the shoulder of the plaque, an areaThere is considerable evidence to support the theory
rich in macrophages.14 The production of MMPs inthat acute plaque changes immediately precede the
this region has been shown to be significantly higheronset of clinical symptoms. Histological studies have
than in other parts of the plaque.15 MMP activity inshown that plaque rupture,2 intra-plaque haemorrhage
coronary plaques has been shown to correlate closelyand overlying thrombus3 are significantly more com-
with the onset of unstable angina, and of particularmon in patients with recent symptoms compared to
interest are the gelatinases, MMP-2 and MMP-9.6those without. Significant disease progression is three
MMP-2 is constitutively expressed in vasculartimes more likely to be identified on Duplex ultrasound
smooth muscle cells in normal arteries and plaquesin patients immediately after an ischaemic event than
exhibit increased levels of expression. Plaques pronein patients who have remained asymptomatic.4
to acute disruption also exhibit induction and ac-Recent work suggests that each phase of the athero-
tivation of MMP-9 in smooth muscle cells and in-sclerotic process may be mediated by a series of en-
flammatory macrophages. More recently, the level ofzymes called matrix metalloproteinases or MMPs,5–7
MMP-9 has been shown to be four times higher in
the most unstable plaques based on symptomatology,
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most at risk of disruption towards which phar- Blood sampling and immunoassay
macotherapy could be targeted.
Reports have suggested that the levels of MMPs Blood samples were drawn from the peripheral vein
of each patient 24 h preoperatively. For the preparationare elevated not only in affected tissue but also in
peripheral blood in patients with cancer, arthritis and of plasma 2Na-EDTA (final 0.1%) was added to whole
blood. Following centrifugation, plasma was siphonedmore recently acute coronary syndromes.17,18 This
raises the possibility that patients at risk of acute into freezing vials, snap frozen in liquid nitrogen and
stored at −80 °C.plaque disruption may have elevated blood levels of
MMPs. MMP and TIMP quantification was performed using
ELISA techniques for MMP-1, MMP-2, MMP-3, MMP-The aim of this study was to investigate the plasma
levels of the major MMP and TIMP (tissue inhibitor 9, TIMP-1, TIMP-2 and TIMP-1/MMP-1 complex using
Biotrak assay systems (Amersham, Amersham, Bucks,of MMP) subtypes in patients undergoing carotid en-
darterectomy to ascertain any differences in those with U.K.), validated for use with human plasma.17 These
provide a specific and precise quantitative de-spontaneous particulate embolisation, probably the
most sensitive indicator of plaque instability.19 termination of enzyme levels and are based on a two-
site ELISA sandwich format, employing two antibodies
directed against different epitopes of the enzyme.
During the first incubation step, MMP present in
Materials and Methods the tissue homogenate binds to a microtitre plate
precoated with antibody. During the second incubation
Seventy-five consecutive patients admitted for carotid step, detection antibody coated with horseradish per-
endarterectomy (CEA) into a single vascular surgical oxidase (HP) is added, which forms an immobilised
unit were entered into this study. Local ethical com- complex. The amount of peroxidase bound to each well
mittee approval was obtained for the procurement of is determined by the addition of tetramethylbenzidine
specimens and all patients gave full informed consent (TMB). The reaction is stopped by the addition of an
for the study. A clinical history was obtained from acid solution and the resultant colour measured at
each patient, with particular care taken to establish 450 nm in a microtitre plate spectrophotometer. The
the number and duration of ischaemic events. All concentration of enzyme is determined by in-
patients underwent a thorough neurological ex- terpolation from a standard curve.
amination. Focal cerebral ischaemic events were de- The MMP-2 and MMP-9 assays recognise free and
fined as transient ischaemic attack, amaurosis fugax, TIMP complexed pro-enzyme only, showing no cross-
central retinal artery occlusion or cerebrovascular ac- reactivity with activated forms of the enzyme nor other
cident. All patients were on long-term aspirin therapy MMPs. The MMP-1 and MMP-3 assays recognise total
(75 or 150 mg daily) and underwent a pre-operative enzyme both active and latent, plus enzyme complexed
Duplex ultrasound assessment of the carotid plaque with TIMPs. The TIMP-1/MMP-1 complex assay re-
for quantification of the degree of stenosis. cognises activated MMP-1 that has subsequently been
Preoperatively patients were monitored with trans- complexed with TIMP-1, but not free MMP-1 or TIMP-
cranial Doppler (TCD) for 30 min, plus intraoperatively 1.The TIMP-1 assay recognises all TIMP-1, both free
during the dissection phase of the operation. This and complexed with MMPs, while the TIMP-2 assay
aimed to identify those with ongoing particulate micro- detects all TIMP-2 except that bound to pro-MMP-2.
embolisation, highly indicative of plaque instability.19
Continuous TCD monitoring of the ipsilateral middle
cerebral artery was performed using a SciMed PC Dop
842 TCD (SciMed, Bristol, U.K.). Signals were recorded
onto digital audio-tape for off line analysis and in- Statistical analysis
terpretation of embolic signals as described pre-
viously.20 For the purpose of this study, emboli were All results are expressed as median values and inter-
quartile ranges. Risk factors were analysed using theonly recorded if they occurred in the preoperative
period or the dissection phase of the operation and, chi-squared test, whilst differences in MMP levels
were analysed using the non-paired, non-parametricafter internal carotid artery clamping, recording was
discontinued. This was to ensure that all recorded Mann–Whitney U-test. Significance was assumed with
a p value <0.05. Logistic regression analysis was per-emboli represented spontaneous dislodgement of par-
ticulate matter from the plaque rather than air emboli formed using the SPSS 8.0 statistical package and the
individual risk factors expressed as a relative risk.and/or thrombus relating to the surgical procedure.
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Table 1. Demographics of patient groups. There were no significant Table 2. The concentrations (ng/ml, median (iqr)) of the major
MMP and TIMP subtypes excluding MMP-9. There were nodifferences between those patients with emboli compared to those
without. significant differences between the groups.
Emboli positive Emboli negativeEmboli positive Emboli negative
n=21 n=49 n=21 n=49
MMP-1 4.6 5.4Age: median (range) 68 (46–80) 68 (46–82)
Male:Female ratio 7:14 18:31 (4.4–6.4) (3.3–6.4)
MMP-2 991 921Asymptomatic 3 (14%) 17 (35%)
Smoker – current 5 (24%) 12 (24%) (787–1088) (719–1088)
MMP-3 10.0 10.2– past 14 (67%) 33 (67%)
IHD 14 (67%) 21 (43%) (7.3–14.4) (7.3–14.1)
MMP-1/TIMP-1 2.9 2.2Hypertension 13 (62%) 31 (63%)
Diabetes 5 (24%) 9 (18%) complex (1.7–4.1) (0.4–4.7)
TIMP-1 249 254Hyperlipidaemia 3 (14%) 11 (22%)
(182–362) (182–351)
TIMP-2 499 532
(469–583) (475–584)Results
Table 3. Logistic regression analysis revealed that the only sig-Five patients were excluded from the study because
nificant predictor of embolisation was a plasma MMP-9 levelthey had no transcranial window, preventing the de- of >30.2 ng/ml (the median value for the entire patient cohort),
tection of emboli. Of the remaining 70 patients, spon- equating to a relative risk of 2.54.
taneous particulate embolisation was detected in 21,
Risk factor for embolisation p-value Relative riskwith 49 showing no evidence of embolisation. The
median number of emboli detected in the emboli Plasma [MMP-9] >30.2 ng/ml 0.05 2.54
Age >68 years 0.70 1.02positive patients was 4 (range 1–16). The clinical char-
Sex 0.64 0.90acteristics of these two groups are shown in Table 1. Symptoms 0.09 2.40
There were no significant differences between the Current/past smoker 0.92 0.98
IHD 0.10 2.0groups on the basis of known risk factors for athero-
Hypertension 0.30 0.96sclerosis or regular medications. Diabetes 0.95 1.24
All had >70% carotid stenosis on Duplex scanning Hyperlipidaemia 0.08 0.67
with no difference between the groups in the per-
centage stenosis. median concentration of 44 ng/ml (iqr 31–59 ng/ml).
Figure 1 demonstrates the peripheral blood levels The plasma levels of MMP-2 in both groups were
of MMP-9 in patients with or without evidence of very similar (median concentration 921 ng/ml for no
spontaneous particulate embolisation. The level of emboli vs. 991 ng/ml for those with emboli) and close
MMP-9 detected on ELISA was significantly higher in to previously published levels for patients with cor-
patients with embolisation than those without (p= onary atherosclerosis.
0.03, Mann–Whitney U-test). In the non-embolising The circulating levels of MMP-1, MMP-1/TIMP-1
group, the median MMP-9 level was 26 ng/ml (iqr complex and MMP-3 were very low, with no difference
19–40 ng/ml). This is very similar to the levels pre- between those patients who were embolising and those
viously reported in normal volunteers. In the em- not embolising (Table 2).
bolising group the level was much higher, with a Whilst quite high concentrations of both TIMP-1
and TIMP-2 were detected in plasma of embolising
and non-embolising patients, there were no significant
differences between the groups in either inhibitor
(Table 2).
Logistic regression analysis was performed to assess
whether the plasma level of MMP-9 represented an
independent predictor of embolisation. Taking all
other atherosclerotic risk factors into account and the
presence of neurological symptoms, plasma MMP-9
levels represented the only significant predictor of
embolisation (p=0.05). A plasma MMP-9 level of
greater than 30.2 ng/ml (the median value for the
Fig. 1. Graph demonstrating the significantly higher MMP-9 con- entire patient group) equated to a relative risk ofcentration in embolising patients compared to those without emboli
(p=0.03). embolisation of 2.54 (Table 3). Whilst the presence of
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symptoms and a history of ischaemic heart disease cause an increased MMP-2 and MMP-9 activity,24
whilst further studies have shown that MMP-9 mayincreased the risk of embolisation, they failed to reach
significance. contribute to post-infarction oedema and haem-
orrhage.25 More recently, MMP-2 and MMP-9 levelsAll patients made uneventful postoperative re-
coveries with no perioperative strokes or deaths. have been demonstrated to increase very early within
ischaemic basal ganglia of non-human primates in
parallel with evidence of neurone injury.26 In humans
the level of cerebral MMP-9 has been shown to be
Discussion high in association with an inflammatory infiltration
predominantly of leukocytes in patients who died
The present study showed increased plasma levels shortly after a stroke.27
of MMP-9 in those patients with significant carotid Increased cerebral levels of MMP-9 may therefore
stenoses undergoing carotid endarterectomy in whom contribute to early disruption of the microvascular
spontaneous particulate embolisation was detected. basal lamina and accentuate neuronal injury. The cellu-
There were no differences in the circulating levels of lar source of cerebral MMPs remains unclear but focal
other MMPs or their naturally occurring inhibitors, cerebral ischaemia may influence plasma MMP levels
TIMPs-1 and -2. This suggests a shift in the balance and vice versa.
of circulating proteolytic enzymes towards proteolysis, Ji Hoe Heo and colleagues demonstrated a transient
a process that is usually tightly controlled. rise in circulating MMP-9 levels in a rat model of
This may represent one of two phenomena. Firstly, middle cerebral artery occlusion.26 However, there are
it may reflect a systemic manifestation of the localised no previous reports linking plasma MMP levels with
increase in MMP-9 levels and activity previously dem- markers of plaque instability. Circulating levels of both
onstrated within unstable plaques, occurring in tan- MMP-2 and MMP-9 have been shown to increase in
dem with intense localised inflammation and tissue patients with acute coronary syndromes. Kai et al.
degradation. MMPs are now recognised to play a key measured plasma MMP levels in 33 patients with acute
role in many aspects of the atherosclerotic process, coronary syndromes, 17 patients with stable angina
but particularly the onset of instability and plaque and 17 normal controls.18 Early increases in circulating
rupture. The intraplaque level, activity and expression levels of both MMP-2 and MMP-9 were demonstrated
of MMP-9 has been shown to be significantly higher in patients with acute coronary syndromes, higher
in the most unstable plaques based on patient symp- than both normal controls and those with stable an-
tomatology, spontaneous embolisation and histo- gina. These results support those of the current paper,
logical features on instability.16 There may be an though we recognise the possibility of a chance finding
increased release of the enzyme into the circulation and the need for larger scale studies.
from the plaque itself, or by circulating macrophages Further investigations are required to address the
involved in the inflammatory response promoting cellular source of the increased circulating MMP-9
plaque degradation. In acute coronary syndromes, levels observed in embolising patients. However, it
for example, monocytes in the systemic circulation may represent a useful marker of plaque instability or
undergo activation and may represent a source of the general level of atherosclerosis-related in-
enzyme.21 flammation and perhas identify a cohort of patients
The increase may on the other hand represent a who warrant urgent intervention.
marker of end organ ischaemia in the form of thrombo-
embolic cerebral damage. CT scans were not per-
formed in this study to look specifically for evidence
of infarction because previous studies of particulate Acknowledgements
embolisation have found that CT is unhelpful in this
Funding from the Stroke Association and The Royal College ofregard.22 A more sensitive measure of end organ dam-
Surgeons of England.age may be psychometric testing and previous studies
have shown a clear link between particulate em-
bolisation and a deterioration in psychological scor-
ing.19
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